Timber Pharmaceuticals, Inc.
COMPOSITIONS AND METHODS FOR TREATING CUTANEOUS FIBROSIS

Last updated:

Abstract:

The present invention relates to local or topical compositions containing a therapeutically effective amount of a selective endothelin-A (ET-A) receptor antagonist or inhibitor, preferably sitaxentan, and pharmaceutically acceptable salts thereof. The compositions are useful for treating a patient that has a condition involving cutaneous fibrosis or connective tissue disease.

Status:
Application
Type:

Utility

Filling date:

4 Mar 2019

Issue date:

11 Feb 2021